Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification

Journal of Clinical Microbiology

Volumn 42, Issue 1, 2004, Pages 421-425

  Morishima, Chihiro ^a   Chung, Minjun ^a   Ng, Ka Wing ^a   Brambilla, Donald J ^b   Gretch, David R ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; BACTERIUM IDENTIFICATION; BIOASSAY; DIAGNOSTIC TEST; HEPATITIS C VIRUS; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VIRUS CONCENTRATION;

HEPACIVIRUS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0345831996     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.1.421-425.2004     Document Type: Article

References (23)

1. Beld, M., R. Sentjens, S. Rebers, C. Weegink, J. Weel, C. Sol, and R. Boom. 2002. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J. Clin. Microbiol. 40:788-793.
2. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
3. Detmer, J., R. Lagier, J. Flynn, C. Zayati, J. Kolberg, M. Collins, M. Urdea, and R. Sanchez-Pescador. 1996. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J. Clin. Microbiol. 34:901-907.
4. Erice, A., D. Brambilla, J. Bremer, J. B. Jackson, R. Kokka, B. Yen-Lieberman, and R. W. Coombs. 2000. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 38:2837-2845.
5. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffmann, and J. Yu. 2002. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
6. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500. (Erratum, 40:1885.)
7. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500. (Erratum, 40:1885.)
8. Hanley, J. P., L. M. Jarvis, J. Andrew, R. Dennis, P. C. Hayes, J. Piris, R. Lee, P. Simmonds, and C. A. Ludlam. 1996. Interferon treatment for chronic hepatitis C infection in hemophiliacs-influence of virus load, genotype, and liver pathology on response. Blood 87:1704-1709.
9. Hino, K., M. Okuda, T. Konishi, H. Ishiko, and K. Okita. 1995. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig. Dis. Sci. 40:14-20.
10. Karino, Y., J. Toyota, M. Sugawara, K. Higashino, T. Sato, T. Ohmura, T. Suga, Y. Okuuchi, and T. Matsushima. 1997. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 92:61-65.
11. Kleter, G. E., J. T. Brouwer, R. A. Heijtink, S. W. Schalm, and W. G. Quint. 1993. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob. Agents Chemother. 37:595-597.
12. Konnick, E. Q., M. Erali, E. R. Ashwood, and D. R. Hillyard. 2002. Performance characteristics of the COBAS Amplicor hepatitis C virus (HCV) monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J. Clin. Microbiol. 40:768-773.
13. Lee, S. C., A. Antony, N. Lee, J. Leibow, J. Q. Yang, S. Soviero, K. Gutekunst, and M. Rosenstraus. 2000. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanccd genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38:4171-4179.
14. Lee, W. M., K. R. Reddy, M. J. Tong, M. Black, D. J. vanLeeuwen, F. B. Hollinger, K. D. Mullen, N. Pimstone, D. Albert, and S. Gardner. 1998. Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 28:1411-1415.
15. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
16. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
17. Mellor, J., A. Hawkins, and P. Simmonds. 1999. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J. Clin. Microbiol. 37:2525-2532.
18. Orito, E., M. Mizokami, K. Suzuki, K. Ohba, T. Ohno, M. Mori, K. Hayashi, K. Kato, S. Iino, and J. Y. Lau. 1995. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J. Med. Virol. 46:109-115.
19. Saldanha, J., N. Lelie, and A. Heath. 1999. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang. 76:149-158.
20. Sherman, K. E., S. D. Rouster, and P. S. Horn. 2002. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin. Infect. Dis. 35:482-487.
21. Shiffman, M. L., A. Ferreira-Gonzalez, K. R. Reddy, R. K. Sterling, V. A. Luketic, R. T. Stravitz, A. J. Sanyal, C. T. Garrett, M. De Medina, and E. R. Schiff. 2003. Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am. J. Gastroenterol. 98:1159-1166.
22. Tong, M. J., L. M. Blatt, J. G. McHutchison, R. L. Co, and A. Conrad. 1997. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 26:1640-1645.
23. Trimoulet, P., P. Halfon, E. Pohier, H. Khiri, G. Chene, and H. Fleury. 2002. Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:2031-2036.